成纤维细胞在特发性肺纤维化发病机制及治疗中的研究进展  

Research progress of fibroblasts in the pathogenesis and treatment of idiopathic pulmonary fibrosis

作　　者：赵娜[1] 夏光涛[1] 张源潮[1] 孙红胜[1] 

机构地区：[1]山东大学附属省立医院风湿免疫科,济南250021

出　　处：《世界临床药物》2013年第7期439-442,共4页World Clinical Drug

摘　　要：目前治疗特发性肺纤维化(IPF)的主要药物为糖皮质激素和免疫抑制剂,但其疗效尚未获得明确的临床证据。IPF中的主要效应细胞为成纤维细胞,干扰成纤维细胞的增殖对抑制IPF的进展有重要的临床意义。本文重点论述IPF的诊断标准并综述成纤维细胞在IPF发病机制及治疗中的研究进展。Glucocorticoids and immunosuppressive agents are usually used for the treatment of idiopathic pulmonary fibrosis （IPF）. However, there is still no clear evidence for the role of these drugs. Fibroblasts are the major cell responsible for IPF. Interference on the proliferation of fibroblasts has important significance in inhibiting the progress of IPF. This review focuses on the diagnosis of IPF and describes the progress of fibroblasts in the pathogenesis and treatment of idiopathic pulmonary fibrosis.

关 键 词：特发性肺纤维化 成纤维细胞 药物治疗 

分 类 号：R563.9[医药卫生—呼吸系统] R974[医药卫生—内科学]